Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/192049 |
Resumo: | OBJECTIVES: The coronavirus disease (COVID-19) outbreak has catastrophically threatened public health worldwide and presented great challenges for clinicians. To date, no specific drugs are available against severe acute respiratory syndrome coronavirus 2. Mesenchymal stem cells (MSCs) appear to be a promising cell therapy owing to their potent modulatory effects on reducing and healing inflammation-induced lung and other tissue injuries. The present pilot study aimed to explore the therapeutic potential and safety of MSCs isolated from healthy cord tissues in the treatment of patients with COVID-19. METHODS: Twelve patients with COVID-19 treated with MSCs plus conventional therapy and 13 treated with conventional therapy alone (control) were included. The efficacy of MSC infusion was evaluated by changes in oxygenation index, clinical chemistry and hematology tests, immunoglobulin (Ig) levels, and pulmonary computerized tomography (CT) imaging. The safety of MSC infusion was evaluated based on the occurrence of allergic reactions and serious adverse events. RESULTS: The MSC-treated group demonstrated significantly improved oxygenation index. The area of pulmonary inflammation decreased significantly, and the CT number in the inflammatory area tended to be restored. Decreased IgM levels were also observed after MSC therapy. Laboratory biomarker levels at baseline and after therapy showed no significant changes in either the MSC-treated or control group. CONCLUSION: Intravenous infusion of MSCs in patients with COVID-19 was effective and well tolerated. Further studies involving a large cohort or randomized controlled trials are warranted. |
id |
USP-19_cd6c4cf74bf30248b54ab5d43c252656 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/192049 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19COVID-19CoronavirusMesenchymal Stem CellsStem Cell TherapyOBJECTIVES: The coronavirus disease (COVID-19) outbreak has catastrophically threatened public health worldwide and presented great challenges for clinicians. To date, no specific drugs are available against severe acute respiratory syndrome coronavirus 2. Mesenchymal stem cells (MSCs) appear to be a promising cell therapy owing to their potent modulatory effects on reducing and healing inflammation-induced lung and other tissue injuries. The present pilot study aimed to explore the therapeutic potential and safety of MSCs isolated from healthy cord tissues in the treatment of patients with COVID-19. METHODS: Twelve patients with COVID-19 treated with MSCs plus conventional therapy and 13 treated with conventional therapy alone (control) were included. The efficacy of MSC infusion was evaluated by changes in oxygenation index, clinical chemistry and hematology tests, immunoglobulin (Ig) levels, and pulmonary computerized tomography (CT) imaging. The safety of MSC infusion was evaluated based on the occurrence of allergic reactions and serious adverse events. RESULTS: The MSC-treated group demonstrated significantly improved oxygenation index. The area of pulmonary inflammation decreased significantly, and the CT number in the inflammatory area tended to be restored. Decreased IgM levels were also observed after MSC therapy. Laboratory biomarker levels at baseline and after therapy showed no significant changes in either the MSC-treated or control group. CONCLUSION: Intravenous infusion of MSCs in patients with COVID-19 was effective and well tolerated. Further studies involving a large cohort or randomized controlled trials are warranted.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2021-11-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/19204910.6061/clinics/2021/e2604Clinics; Vol. 76 (2021); e2604Clinics; v. 76 (2021); e2604Clinics; Vol. 76 (2021); e26041980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/192049/176971Copyright (c) 2021 Clinicsinfo:eu-repo/semantics/openAccessWei, Fengtao Kong, Dexiao Li, Tao Li, Ai Tan, Yi Fang, Jinfeng Zhuang, Xianghua Lai, Chao Xu, Weihua Dong, Hong Ma, Chengen Hong, Ke Cui, Yuqin Tang, Shengbin Yu, Fenggang Zheng, Chengyun 2023-07-06T13:04:03Zoai:revistas.usp.br:article/192049Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2023-07-06T13:04:03Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
title |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
spellingShingle |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 Wei, Fengtao COVID-19 Coronavirus Mesenchymal Stem Cells Stem Cell Therapy |
title_short |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
title_full |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
title_fullStr |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
title_full_unstemmed |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
title_sort |
Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19 |
author |
Wei, Fengtao |
author_facet |
Wei, Fengtao Kong, Dexiao Li, Tao Li, Ai Tan, Yi Fang, Jinfeng Zhuang, Xianghua Lai, Chao Xu, Weihua Dong, Hong Ma, Chengen Hong, Ke Cui, Yuqin Tang, Shengbin Yu, Fenggang Zheng, Chengyun |
author_role |
author |
author2 |
Kong, Dexiao Li, Tao Li, Ai Tan, Yi Fang, Jinfeng Zhuang, Xianghua Lai, Chao Xu, Weihua Dong, Hong Ma, Chengen Hong, Ke Cui, Yuqin Tang, Shengbin Yu, Fenggang Zheng, Chengyun |
author2_role |
author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Wei, Fengtao Kong, Dexiao Li, Tao Li, Ai Tan, Yi Fang, Jinfeng Zhuang, Xianghua Lai, Chao Xu, Weihua Dong, Hong Ma, Chengen Hong, Ke Cui, Yuqin Tang, Shengbin Yu, Fenggang Zheng, Chengyun |
dc.subject.por.fl_str_mv |
COVID-19 Coronavirus Mesenchymal Stem Cells Stem Cell Therapy |
topic |
COVID-19 Coronavirus Mesenchymal Stem Cells Stem Cell Therapy |
description |
OBJECTIVES: The coronavirus disease (COVID-19) outbreak has catastrophically threatened public health worldwide and presented great challenges for clinicians. To date, no specific drugs are available against severe acute respiratory syndrome coronavirus 2. Mesenchymal stem cells (MSCs) appear to be a promising cell therapy owing to their potent modulatory effects on reducing and healing inflammation-induced lung and other tissue injuries. The present pilot study aimed to explore the therapeutic potential and safety of MSCs isolated from healthy cord tissues in the treatment of patients with COVID-19. METHODS: Twelve patients with COVID-19 treated with MSCs plus conventional therapy and 13 treated with conventional therapy alone (control) were included. The efficacy of MSC infusion was evaluated by changes in oxygenation index, clinical chemistry and hematology tests, immunoglobulin (Ig) levels, and pulmonary computerized tomography (CT) imaging. The safety of MSC infusion was evaluated based on the occurrence of allergic reactions and serious adverse events. RESULTS: The MSC-treated group demonstrated significantly improved oxygenation index. The area of pulmonary inflammation decreased significantly, and the CT number in the inflammatory area tended to be restored. Decreased IgM levels were also observed after MSC therapy. Laboratory biomarker levels at baseline and after therapy showed no significant changes in either the MSC-treated or control group. CONCLUSION: Intravenous infusion of MSCs in patients with COVID-19 was effective and well tolerated. Further studies involving a large cohort or randomized controlled trials are warranted. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/192049 10.6061/clinics/2021/e2604 |
url |
https://www.revistas.usp.br/clinics/article/view/192049 |
identifier_str_mv |
10.6061/clinics/2021/e2604 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/192049/176971 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 76 (2021); e2604 Clinics; v. 76 (2021); e2604 Clinics; Vol. 76 (2021); e2604 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222765688553472 |